Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis

Journal of Cystic Fibrosis

Volumn 13, Issue 5, 2014, Pages 542-549

  Daines, Cori ^a   VanDeVanter, Donald ^b   Khan, Umer ^c   Emerson, Julia ^d   Heltshe, Sonya ^d   McNamara, Sharon ^d   Anstead, Michael ^e   Langkamp, Markus ^f   Doring, Gerd ^g   Ratjen, Felix ^h   Ramsey, Bonnie ^d   Gibson, Ronald L ^d   Morgan, Wayne ^a   Rosenfeld, Margaret ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f Mediagnost   (Germany)

^g UNIVERSITY OF TÜBINGEN   (Germany)

^h HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cystic fibrosis; Pseudomonas; ROC curves; Serology

Indexed keywords

ALKALINE PROTEINASE; ANTIBODY; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ELASTASE; EXOTOXIN; BACTERIUM ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; ASSOCIATION; BACTERIUM CULTURE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; GENOTYPE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PANCREAS INSUFFICIENCY; PREDICTIVE VALUE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEROLOGY; COMPLICATION; FORECASTING; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; OROPHARYNX; PSEUDOMONAS INFECTIONS; STATISTICAL MODEL;

ANTIBODIES, BACTERIAL; CHILD; CYSTIC FIBROSIS; FEMALE; FORECASTING; HUMANS; LOGISTIC MODELS; MALE; OROPHARYNX; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84926130841     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.06.005     Document Type: Article

References (46)

1. Doring G. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Int J Med Microbiol 2010, 300:573-577.
2. Burns J.L., Gibson R.L., McNamara S., Yim D., Emerson J., Rosenfeld M., et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001, 183:444-452.
3. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G., et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293:581-588.
4. Rosenfeld M., Emerson J., Accurso F., Armstrong D., Castile R., Grimwood K., et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr Pulmonol 1999, 28:321-328.
5. Cystic Fibrosis Foundation Cystic Fibrosis Foundation Patient Registry. Annual Data Report 2012, MD2013. [Bethesda].
6. Konstan M.W., Morgan W.J., Butler S.M., Pasta D.J., Craib M.L., Silva S.J., et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007, 151:134-139. [9 e1].
7. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001, 32:277-287.
8. Henry R.L., Mellis C.M., Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992, 12:158-161.
9. Demko C.A., Byard P.J., Davis P.B. Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 1995, 48:1041-1049.
10. Starner T.D., McCray P.B. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005, 143:816-822.
11. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009, CD004197.
12. Ratjen F., Munck A., Kho P., Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010, 65:286-291.
13. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165:847-856.
14. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-335.
15. Hoiby N., Frederiksen B., Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 2005, 4(Suppl. 2):49-54.
16. Taccetti G., Campana S., Festini F., Mascherini M., Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26:458-461.
17. Douglas T.A., Brennan S., Berry L., Winfield K., Wainwright C.E., Grimwood K., et al. Value of serology in predicting Pseudomonas aeruginosa infection in young children with cystic fibrosis. Thorax 2010, 65:985-990.
18. Saiman L., Cohen M.B. What have we learned about early treatment of Pseudomonas aeruginosa infection in infants and children with cystic fibrosis?. Arch Pediatr Adolesc Med 2011, 165:867-868.
19. Lee T.W., Brownlee K.G., Conway S.P., Denton M., Littlewood J.M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003, 2:29-34.
20. Emerson J., Rosenfeld M., McNamara S., Ramsey B., Gibson R.L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100.
21. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., Rosenfeld M., Retsch-Bogart G., Treggiari M.M., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012, 47:125-134.
22. Mauch R.M., Levy C.E. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. J Cyst Fibros 2014, 13:497-505.
23. Pedersen S.S., Espersen F., Hoiby N. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay. J Clin Microbiol 1987, 25:1830-1836.
24. Kappler M., Kraxner A., Reinhardt D., Ganster B., Griese M., Lang T. Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis. Thorax 2006, 61:684-688.
25. Brett M.M., Ghoneim A.T.M., Littlewood J.M. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child 1986, 61:1114-1120.
26. Farrell P.M., Govan J.R. Pseudomonas serology: confusion, controversy, and challenges. Thorax 2006, 61:645-647.
27. da Silva Filho L.V., Tateno A.F., Martins K.M., Azzuz Chernishev A.C., Garcia Dde O., Haug M., et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol 2007, 42:938-944.
28. Tramper-Stranders G.A., van der Ent C.K., Slieker M.G., Terheggen-Lagro S.W., Teding van Berkhout F., Kimpen J.L., et al. Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006, 61:689-693.
29. Hayes D., Farrell P.M., Li Z., West S.E. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol 2010, 45:55-61.
30. Ratjen F., Walter H., Haug M., Meisner C., Grasemann H., Doring G. Diagnostic value of serum antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis patients. Pediatr Pulmonol 2007, 42:249-255.
31. West S.E., Zeng L., Lee B.L., Kosorok M.R., Laxova A., Rock M.J., et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002, 287:2958-2967.
32. Rosenfeld M., Emerson J., McNamara S., Joubran K., Retsch-Bogart G., Graff G.R., et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010, 45:934-944.
33. Farrell P.M., Rosenstein B.J., White T.B., Accurso F.J., Castellani C., Cutting G.R., et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008, 153:S4-S14.
34. Rosenfeld M., Emerson J., McNamara S., Thompson V., Ramsey B.W., Morgan W., et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros 2012, 11:446-453.
35. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
36. Zemanick E., Emerson J., Thompson V., McNamara S., Morgan W., Gibson R., et al. Clinical outcomes after initial Pseudomonas acquisition in cystic fibrosis. Pediatr Pulmonol 2014 Mar 18, [Epub ahead of print].
37. Anstead M., Heltshe S.L., Khan U., Barbieri J.T., Langkamp M., Döring G., et al. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. J Cyst Fibros 2013, 12:147-153.
38. Pressler T., Karpati F., Granstrom M., Knudsen P.R., Lindblad A., Hjelte L., et al. Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009, 8:37-42.
39. Pressler T., Kronborg G., Shand G.H., Mansa B., Hoiby N. Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay. Med Microbiol Immunol 1992, 181:339-349.
40. Fomsgaard A., Dinesen B., Shand G.H., Pressler T., Hoiby N. Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. J Clin Microbiol 1989, 27:1222-1229.
41. Pressler T., Pedersen S.S., Espersen F., Hoiby N., Koch C. IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA. Clin Exp Immunol 1990, 81:428-434.
42. van Ewijk B.E., Wolfs T.F., Fleer A., Kimpen J.L., van der Ent C.K. High Pseudomonas aeruginosa acquisition rate in CF. Thorax 2006, 61:641-642.
43. Aanaes K., Johanse H.K., Poulsen S.S., Pressler T., Buchwald C., Hoiby N. Secretory IgA as a diagnostic tool for Pseudomonas aeruginosa respiratory colonization. J Cyst Fibros 2013, 12:81-87.
44. Campodonico V.L., Llosa N.J., Grout M., Doring G., Maira-Litran T., Pier G.B. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect Immun 2010, 78:746-755.
45. Nelson J.W., Govan J.R.W., Barclay G.R. Pseudomonas aeruginosa flagellar antibodies in serum, saliva and sputum from patients with cystic fibrosis. Serodiagn Immunother Infect Dis 1990, 4:351-361.
46. Green D.M., McDougal K.E., Blackman S.M., Sosnay P.R., Henderson L.B., Naughton K.M., et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir Res 2010, 11:140.